A perspective on Rare Cancer Day. This year more than 600,000 lives in the US will be lost to cancer. The five most common malignancies account for half of these deaths. Most of the victims are elderly; fewer than 2% of cancer fatalities occur under age 40. Rarer cancers, especially those affecting youthful patients, receive …
Congratulations to Marina Baretti, MD who was installed as the inaugural recipient of the Jiasheng Professorship in Hepato-Biliary Cancer Research at the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center. Dr. Baretti has been actively involved in both FLC patient care and research. She has been instrumental to several path breaking research efforts for this disease, …
In a study funded by FCF, scientists at Cornell University analyzed the differences in the proteins and metabolites present in fibrolamellar carcinoma (FLC) and normal tissues to better understand the metabolism of the disease. Their findings, published in Cell Reports Medicine on August 28, offer deep insights into the metabolic alterations that occur in FLC, …
A new era in cancer therapy dawned in 2011 when the FDA approved ipilimumab (Yervoy) to treat metastatic melanoma. This was the first of a novel class of drugs called immune checkpoint inhibitors (ICIs), which “take the brakes off” the immune system’s ability to kill cancer cells. Today eleven different ICIs are available in the …
Here’s your chance to double your impact on fibrolamellar research! Thanks to the generosity of the Chuck & Marna Davis family …
“You are what you eat” is a phrase popularized by the American nutritionist Victor Lindlahr in the 1930s. Of course, the body’s cells have no way to determine whether the nutrients that reach them come from a four-star gourmet meal or a hot dog on a bun. However, for years, it has been recognized that …
Virtual registration is still open for FCF’s second Fibrolamellar Patient & Research Summit to be held on Sunday, June 9 through Monday, June 10 in Greenwich, Connecticut. This summit is meant to be a collaborative working session in which fibrolamellar patients, caregivers, clinicians and researchers discuss the current state of FLC research, share perspectives, and …
Below is a discussion of the implications of recent research efforts on future FLC immunotherapy treatments as summarized by Mark Furth …
FCF is pleased to announce that it has awarded a grant to Sean Ronnekleiv-Kelly, MD of the University of Wisconsin-Madison School of Medicine to determine if targeting CDK7 could be a useful treatment approach for FLC. A group of proteins called cyclin-dependent kinases (CDKs) help regulate cell division and other fundamental cellular processes. Previously, Dr. …